Search results
Showing 571 to 585 of 985 results for drug therapy
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS115Show all sections
Sections for QS115
- Quality statements
- Quality statement 1: Valproate
- Quality statement 2: Pre-conception information
- Quality statement 3: Information for pregnant women
- Quality statement 4: Asking about mental health and wellbeing
- Quality statement 5: Comprehensive mental health assessment
- Quality statement 6: Psychological interventions
- Quality statement 7 (developmental): Specialist multidisciplinary perinatal mental health services
This quality standard covers diagnosing and managing bladder cancer in adults (aged 18 and over) referred from primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS106Show all sections
Sections for QS106
- Quality statements
- Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour
- Quality statement 2: Chemotherapy during transurethral resection of bladder tumour
- Quality statement 3: Access to a clinical nurse specialist
- Quality statement 4: Risk classification
- Quality statement 5: Discussing treatment options for high-risk non-muscle-invasive bladder cancer
- Quality statement 6: Discussing treatment options for muscle-invasive urothelial bladder cancer
- Quality statement 7: Discharge to primary care
Find out more about NICE technology appraisals advisory committee D members
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
View quality statements for QS68Show all sections
Sections for QS68
- Quality statements
- Quality statement 1: Diagnosis of acute myocardial infarction
- Quality statement 2: Risk assessment for adults with NSTEMI or unstable angina
- Quality statement 3: Coronary angiography and PCI within 72 hours for NSTEMI or unstable angina
- Quality statement 4: Coronary angiography and PCI for adults with NSTEMI or unstable angina who are clinically unstable
- Quality statement 5: Level of consciousness and eligibility for coronary angiography and primary PCI
- Quality statement 6: Primary PCI for acute STEMI
- Update information
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)
Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.
Next-generation sequencing panel for solid tumour cancers in children (MIB133)
NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .